Volume 19, Number 4—April 2013
CME ACTIVITY - Research
Serotype IV and Invasive Group B Streptococcus Disease in Neonates, Minnesota, USA, 2000–20101
Table 4
Clindamycin susceptibility profiles of GBS isolates from 45 infants with invasive GBS disease, Minnesota, USA, 2010*
Antimicrobial susceptibility profile† |
CPS serotype |
Total | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Clindamycin | Erythromycin | D-test | Ia | Ib | II | III | IV | V | ||
S | S | Not done | 7 | 1 | 0 | 13 | 1 | 2 | 24 | |
S | R | Negative | 4 | 0 | 0 | 3 | 0 | 0 | 7 | |
S→R | R | Positive | 1 | 1 | 0 | 2 | 0 | 0 | 4 | |
R |
R |
Not done |
0 |
2 |
1 |
0 |
4 |
3 |
10 |
|
Total no. | 12 | 4 | 1 | 18 | 5 | 5 | 45 | |||
No. (%) resistant | 1 (8.3) | 3 (75.0) | 1 | 2 (11.1) | 4 (80.0) | 3 (60.0) | 14 (31.1) |
*GBS, group B Streptococcus; CPS, capsular polysaccharide serotype.
†S, susceptible, MIC <0.25 μg/mL; R, resistant, MIC >1 μg/mL; S→R, inducible resistance to clindamycin indicated by positive D-zone test (double-disk diffusion test).
1This work was presented in part at the XVIII Lancefield International Symposium on Streptococci and Streptococcal Diseases, September 4–8, 2011, Palermo, Italy.